Primary amines on proteins and peptides

Primary amines on proteins and peptides are chemical functional groups located at the N-terminus of polypeptide chains and within the side chains of lysine residues (Thermo Fisher Scientific, 2023). These groups are characterized by their high nucleophilicity at physiological pH, which allows them to participate in a wide range of chemical reactions, including acylation, alkylation, and non-enzymatic glycation (Hermanson, Bioconjugate Techniques, 2013). While not a specific therapeutic target in the traditional sense of a receptor or enzyme, primary amines are critical sites for the chemical modification of therapeutic proteins, such as in the production of Antibody-Drug Conjugates (ADCs) and PEGylated drugs (Beck et al., Nature Reviews Drug Discovery, 2017). In a biological context, the epsilon-amino group of lysine is often essential for protein stability through the formation of salt bridges and is frequently found in the active sites of enzymes where it facilitates catalysis (UniProt, 2024). Endogenous modification of these amines by reducing sugars or reactive aldehydes leads to the formation of Advanced Glycation End-products (AGEs), which are central to the pathology of diabetes, vascular complications, and aging (Bunn et al., Science, 1978). Consequently, these sites are central to both the design of modern biopharmaceuticals and the understanding of protein degradation and disease-related protein damage.

Other names

N-terminal amino groupsEpsilon-amino groups of lysineProtein amino groupsLysine side-chain aminesFree amino groups

Drugs or reagents typically interact with primary amines through nucleophilic substitution or addition reactions. For instance, N-hydroxysuccinimide (NHS) esters react via acylation to form stable amide bonds, while aldehydes react via nucleophilic addition to form reversible Schiff bases that can be stabilized through reductive amination (Hermanson, Bioconjugate Techniques, 2013). These reactions are the fundamental basis for protein labeling, crosslinking, and the synthesis of therapeutic conjugates such as Antibody-Drug Conjugates (ADCs) (Beck et al., Nature Reviews Drug Discovery, 2017).